PCRX Pacira BioSciences Inc

Price (delayed)

$52.53

Market cap

$2.34B

P/E Ratio

37.79

Dividend/share

N/A

EPS

$1.39

Enterprise value

$2.76B

Pacira BioSciences, Inc.is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. The company's long-acting local ...

Highlights
The equity has increased by 23% year-on-year and by 4.6% since the previous quarter
Pacira BioSciences's gross profit has increased by 23% YoY
The company's quick ratio has shrunk by 51% YoY but it rose by 5% QoQ
Pacira BioSciences's EPS has shrunk by 65% QoQ and by 53% YoY
The company's net income has shrunk by 65% QoQ and by 51% YoY

Key stats

What are the main financial stats of PCRX
Market
Shares outstanding
44.54M
Market cap
$2.34B
Enterprise value
$2.76B
Valuations
Price to earnings (P/E)
37.79
Price to book (P/B)
3.25
Price to sales (P/S)
4.55
EV/EBIT
26.62
EV/EBITDA
22.22
EV/Sales
5.38
Earnings
Revenue
$513.31M
EBIT
$103.69M
EBITDA
$124.23M
Free cash flow
$98.06M
Per share
EPS
$1.39
Free cash flow per share
$2.2
Book value per share
$16.16
Revenue per share
$11.54
TBVPS
$26.21
Balance sheet
Total assets
$1.36B
Total liabilities
$637.4M
Debt
$554.56M
Equity
$718.6M
Working capital
$596.56M
Liquidity
Debt to equity
0.77
Current ratio
3.64
Quick ratio
3.29
Net debt/EBITDA
3.39
Margins
EBITDA margin
24.2%
Gross margin
73.4%
Net margin
12%
Operating margin
20.4%
Efficiency
Return on assets
4.7%
Return on equity
9.2%
Return on invested capital
7.8%
Return on capital employed
9.2%
Return on sales
20.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PCRX stock price

How has the Pacira BioSciences stock price performed over time
Intraday
-2.27%
1 week
1.74%
1 month
-6.86%
1 year
-15.32%
YTD
-12.22%
QTD
-6.2%

Financial performance

How have Pacira BioSciences's revenue and profit performed over time
Revenue
$513.31M
Gross profit
$376.77M
Operating income
$104.5M
Net income
$61.63M
Gross margin
73.4%
Net margin
12%
PCRX's operating margin has soared by 191% YoY and by 13% QoQ
The company's net income has shrunk by 65% QoQ and by 51% YoY
Pacira BioSciences's net margin has plunged by 65% from the previous quarter and by 60% YoY
Pacira BioSciences's gross profit has increased by 23% YoY

Growth

What is Pacira BioSciences's growth rate over time

Valuation

What is Pacira BioSciences stock price valuation
P/E
37.79
P/B
3.25
P/S
4.55
EV/EBIT
26.62
EV/EBITDA
22.22
EV/Sales
5.38
Pacira BioSciences's EPS has shrunk by 65% QoQ and by 53% YoY
PCRX's P/E is 61% above its last 4 quarters average of 23.4
PCRX's P/B is 36% below its 5-year quarterly average of 5.1 and 21% below its last 4 quarters average of 4.1
The equity has increased by 23% year-on-year and by 4.6% since the previous quarter
The price to sales (P/S) is 22% lower than the last 4 quarters average of 5.8 and 13% lower than the 5-year quarterly average of 5.2
The revenue has grown by 22% YoY and by 2% from the previous quarter

Efficiency

How efficient is Pacira BioSciences business performance
Pacira BioSciences's return on sales has surged by 197% YoY and by 19% QoQ
Pacira BioSciences's ROIC has soared by 169% YoY and by 22% from the previous quarter
PCRX's ROE has dropped by 69% year-on-year and by 66% since the previous quarter
Pacira BioSciences's ROA has plunged by 65% from the previous quarter and by 65% YoY

Dividends

What is PCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PCRX.

Financial health

How did Pacira BioSciences financials performed over time
The total assets is 113% greater than the total liabilities
The current ratio has plunged by 52% YoY but it has grown by 4.9% from the previous quarter
The company's quick ratio has shrunk by 51% YoY but it rose by 5% QoQ
Pacira BioSciences's debt is 23% less than its equity
The equity has increased by 23% year-on-year and by 4.6% since the previous quarter
Pacira BioSciences's debt to equity has decreased by 16% YoY and by 3.8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.